Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Declines By 56.6%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totaling 56,341 shares, a drop of 56.6% from the July 15th total of 129,920 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 155,428 shares, the days-to-cover ratio is presently 0.4 days.

Hedge Funds Weigh In On Lisata Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Lisata Therapeutics by 6.1% in the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after purchasing an additional 7,093 shares during the last quarter. SOL Capital Management CO acquired a new position in Lisata Therapeutics in the 1st quarter valued at approximately $61,000. Cerity Partners LLC bought a new position in shares of Lisata Therapeutics during the second quarter valued at $32,000. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics during the third quarter valued at $37,000. Finally, Ground Swell Capital LLC lifted its holdings in shares of Lisata Therapeutics by 64.0% during the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after purchasing an additional 15,213 shares during the period. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Stock Down 3.5%

Shares of NASDAQ:LSTA traded down $0.04 during trading on Friday, hitting $1.09. 24,983 shares of the company were exchanged, compared to its average volume of 128,470. The business’s 50 day moving average is $2.64 and its 200-day moving average is $3.63. Lisata Therapeutics has a 1-year low of $0.99 and a 1-year high of $5.07.

Analyst Upgrades and Downgrades

LSTA has been the subject of several research analyst reports. Weiss Ratings downgraded Lisata Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. HC Wainwright cut shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Finally, Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $15.00.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.